

# NATESTO *DIRECT*

## HOW THE PROGRAM WORKS

*NatestoDirect* provides medication to patients nationwide.

*NatestoDirect* will complete the benefits investigation and provide prior authorization assistance

*NatestoDirect* will always stock NATESTO®, and ship NATESTO® directly to the patient's home or office

*NatestoDirect* offers the lowest possible copays available to your patients, Pay As Low As \$0 and Pay No More Than \$149



TO ENROLL YOUR PATIENTS, SEND PRESCRIPTIONS DIRECT TO *NatestoDirect*



### E-SCRIBE

Benzer Pharmacy

- Tampa, FL 33610
- NCPDP # 1041196
- NPI # 1811133424



### FAX

844.772.1288



### CALL-IN

1-833-NATESTO (628-3786)




PLEASE INCLUDE THE FOLLOWING WITH EVERY PRESCRIPTION TO *NatestoDirect*

1. NATESTO® Prescription
2. Patient Demographics
3. Labs/Clinical Notes

SEE INDICATIONS AND USAGE AND IMPORTANT SAFETY INFORMATION ON BACK PAGE

# NATESTO DIRECT

## PRESCRIBE NATESTO®



## INDICATION

### What is NATESTO® (testosterone) Nasal Gel?

NATESTO® is a prescription medicine that contains testosterone and is used to treat adult males who have low or no testosterone due to certain medical conditions. Your doctor will test the testosterone level in your blood before you start and while you are using NATESTO®.

NATESTO® should not be used by men with breast cancer or known or suspected prostate cancer. NATESTO® should not be used by women.

It is not known if NATESTO® is safe or effective to treat men who have low testosterone due to aging.

Safety and effectiveness of NATESTO® have not been established in children younger than 18 years old and NATESTO® should not be used by children. NATESTO® use by children may affect bone growth.

NATESTO® is a controlled substance (CIII) because it contains testosterone that can be a target for people who abuse prescription medicines. Never give your NATESTO® to anyone else.

## IMPORTANT SAFETY INFORMATION

Nasal adverse reactions, including nasopharyngitis, rhinorrhea, epistaxis, nasal discomfort, and nasal scabbing, were reported in the clinical trial experience with NATESTO®. Patients should be instructed to report any nasal symptoms or signs to their healthcare professional. In that circumstance, healthcare professionals should determine whether further evaluation or discontinuation of NATESTO® is appropriate.

- Edema, with or without congestive heart failure, may be a serious complication in patients with pre-existing cardiac, renal, or hepatic disease
- Administration of exogenous androgens, including NATESTO®, may lead to azoospermia through suppression of spermatogenesis; gynecomastia; sleep apnea (especially in patients with risk factors such as obesity and chronic lung disease); decreased concentrations of thyroxine-binding globulins; and changes in serum lipid profile
- NATESTO® should be used with caution in cancer patients at risk of hypercalcemia (and associated hypercalciuria)
- Periodic monitoring of prostate specific antigen (PSA), hematocrit, and lipid concentrations is recommended, as changes may require discontinuation of NATESTO®

**References:** **1.** Natesto® (Prescribing Information). Aytu Bioscience, Inc. Englewood, CO 12/2017. **2.** Pires A, Fortuna A, Alves G, Falcão A. Intranasal drug delivery: how, why and what for? J Pharm Sci. 2009;12(3):288-311. **3.** Bitter C, Suter-Zimmermann K, Surber C. Nasal drug delivery in humans. Curr Probl Dermatol. 2011;40:20-35. **4.** de Ronde W. Hyperandrogenism after transfer of topical gel: case report and review of published and unpublished studies. Hum Reprod. 2009;24(2):425-428. **5.** Patient Market Research. Post-Phase III trial survey results. January 2014.

Please see complete prescribing information at [Natesto.com](http://Natesto.com)



Natesto® is exclusively marketed in the United States by Aytu BioScience and is a trademark of Acerus Pharmaceuticals.